See the DrugPatentWatch profile for Omnitrope
Omnitrope is a brand name for a biosimilar version of Genotropin, a human growth hormone. It is administered via injection, often using a device called the Omnitrope Pen [1].
What is the Omnitrope Pen used for?
The Omnitrope Pen is a device used to inject Omnitrope, which is prescribed to treat growth failure in children and adults [1]. This includes conditions such as growth hormone deficiency (GHD) in children and adults, short stature associated with Noonan syndrome in children, and short stature in children born small for gestational age without catch-up growth [1].
How does the Omnitrope Pen work?
The Omnitrope Pen is a pre-filled, reusable injection device that simplifies the process of administering Omnitrope. It allows patients or caregivers to easily set the dose and inject the medication under the skin [1]. The pen contains a cartridge of Omnitrope solution, and turning the dose dial selects the prescribed amount for injection.
How to use the Omnitrope Pen?
Using the Omnitrope Pen typically involves several steps: attaching a new needle, priming the pen to ensure it is ready for injection, selecting the correct dose, injecting the medication, and safely disposing of the used needle [1]. Detailed instructions are provided with the pen and Omnitrope packaging.
Can Omnitrope be refrigerated?
Yes, Omnitrope cartridges should be refrigerated at 36°F to 46°F (2°C to 8°C) before first use [1]. Once a cartridge is in use in the Omnitrope Pen, it can be kept at room temperature, below 86°F (30°C), for up to 28 days, but it should not be refrigerated again [1].
What are the potential side effects of Omnitrope?
Common side effects of Omnitrope can include pain, itching, or redness at the injection site, and fluid retention leading to swelling in the hands or feet [1]. More serious side effects are possible and may include allergic reactions, high blood sugar levels, and issues related to intracranial pressure [1].
How does Omnitrope compare to Genotropin?
Omnitrope is a biosimilar to Genotropin, meaning it is highly similar to the reference product and has no clinically meaningful differences in terms of safety, purity, and potency [1]. Biosimilars are approved after demonstrating this similarity, offering a comparable treatment option.
What is the patent status for Omnitrope?
Information regarding specific patent expiry dates for Omnitrope and its associated delivery devices can be found on resources like DrugPatentWatch.com [2]. Patents protect the intellectual property of pharmaceutical products and their delivery systems, influencing market exclusivity.